| Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer MP Labrecque, IM Coleman, LG Brown, LD True, L Kollath, B Lakely, ... The Journal of clinical investigation 129 (10), 4492-4505, 2019 | 361 | 2019 |
| Durable response of enzalutamide-resistant prostate cancer to supraphysiological testosterone is associated with a multifaceted growth suppression and impaired DNA damage … HM Lam, HM Nguyen, MP Labrecque, LG Brown, IM Coleman, R Gulati, ... European urology 77 (2), 144-155, 2020 | 62 | 2020 |
| Regulation of CEACAM5 and therapeutic efficacy of an anti-CEACAM5–SN38 antibody–drug conjugate in neuroendocrine prostate cancer DC DeLucia, TM Cardillo, L Ang, MP Labrecque, A Zhang, JE Hopkins, ... Clinical Cancer Research 27 (3), 759-774, 2021 | 61 | 2021 |
| BET bromodomain inhibition blocks an AR-repressed, E2F1-activated treatment-emergent neuroendocrine prostate cancer lineage plasticity program DH Kim, D Sun, WK Storck, K Welker Leng, C Jenkins, DJ Coleman, ... Clinical Cancer Research 27 (17), 4923-4936, 2021 | 60 | 2021 |
| Distinct roles for aryl hydrocarbon receptor nuclear translocator and ah receptor in estrogen-mediated signaling in human cancer cell lines MP Labrecque, MK Takhar, BD Hollingshead, GG Prefontaine, ... PLoS One 7 (1), e29545, 2012 | 59 | 2012 |
| The aryl hydrocarbon receptor nuclear translocator (ARNT) family of proteins: transcriptional modifiers with multi-functional protein interfaces M P. Labrecque, G G. Prefontaine, T V. Beischlag Current molecular medicine 13 (7), 1047-1065, 2013 | 55 | 2013 |
| Estrogen receptor expression is required for low-dose resveratrol-mediated repression of aryl hydrocarbon receptor activity GH Perdew, BD Hollingshead, BC DiNatale, JL Morales, MP Labrecque, ... Journal of Pharmacology and Experimental Therapeutics 335 (2), 273-283, 2010 | 44 | 2010 |
| The retinoblastoma protein regulates hypoxia-inducible genetic programs, tumor cell invasiveness and neuroendocrine differentiation in prostate cancer cells MP Labrecque, MK Takhar, R Nason, S Santacruz, KJ Tam, S Massah, ... Oncotarget 7 (17), 24284, 2016 | 39 | 2016 |
| Epigenetic characterization of the growth hormone gene identifies SmcHD1 as a regulator of autosomal gene clusters S Massah, R Hollebakken, MP Labrecque, AM Kolybaba, TV Beischlag, ... PloS one 9 (5), e97535, 2014 | 38 | 2014 |
| Expression of human inducible nitric oxide synthase in response to cytokines is regulated by hypoxia-inducible factor-1 M Lee, C Wang, SW Jin, MP Labrecque, TV Beischlag, MA Brockman, ... Free Radical Biology and Medicine 130, 278-287, 2019 | 34 | 2019 |
| p, p′-Dichlorodiphenyltrichloroethane (p, p′-DDT) and p, p′-dichlorodiphenyldichloroethylene (p, p′-DDE) repress prostate specific antigen levels in human prostate cancer … LIL Wong, MP Labrecque, N Ibuki, ME Cox, JE Elliott, TV Beischlag Chemico-biological interactions 230, 40-49, 2015 | 34 | 2015 |
| RNA splicing factors SRRM3 and SRRM4 distinguish molecular phenotypes of castration-resistant neuroendocrine prostate cancer MP Labrecque, LG Brown, IM Coleman, B Lakely, NJ Brady, JK Lee, ... Cancer research 81 (18), 4736-4750, 2021 | 30 | 2021 |
| The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches MP Labrecque, JJ Alumkal, IM Coleman, PS Nelson, C Morrissey Endocrine-related cancer 28 (8), T51-T66, 2021 | 30 | 2021 |
| A TRIP230-retinoblastoma protein complex regulates hypoxia-inducible factor-1α-mediated transcription and cancer cell invasion MP Labrecque, MK Takhar, JM Jagdeo, KJ Tam, C Chiu, TY Wang, ... PloS one 9 (6), e99214, 2014 | 15 | 2014 |
| Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature MP Labrecque, LG Brown, IM Coleman, HM Nguyen, DW Lin, E Corey, ... Plos one 16 (1), e0245602, 2021 | 14 | 2021 |
| Retinoblastoma protein (Rb) links hypoxia to altered mechanical properties in cancer cells as measured by an optical tweezer S Khakshour, MP Labrecque, H Esmaeilsabzali, FJS Lee, ME Cox, ... Scientific Reports 7 (1), 7833, 2017 | 10 | 2017 |
| Concurrent targeting of HDAC and PI3K to overcome phenotypic heterogeneity of castration-resistant and neuroendocrine prostate cancers A Zhang, NA Lau, A Wong, LG Brown, IM Coleman, N De Sarkar, D Li, ... Cancer Research Communications 3 (11), 2358-2374, 2023 | 5 | 2023 |
| Targeting the fibroblast growth factor pathway in molecular subtypes of castration‐resistant prostate cancer MP Labrecque, LG Brown, IM Coleman, HM Nguyen, S Dalrymple, ... The Prostate 84 (1), 100-110, 2024 | 4 | 2024 |
| Supraphysiological testosterone inhibits tumor growth and is associated with inhibition of ARV7 signaling and DNA damage response in preclinical models of enzalutamide … HM Lam, MP Labrecque, HM Nguyen, LG Brown, IM Coleman, R Gulati, ... Cancer Research 79 (13_Supplement), 379-379, 2019 | 1 | 2019 |
| Abstract B022: TEAD inhibition overcomes YAP/TAZ-driven resistance to RAS (ON) inhibitors V Vemulapalli, P Dinh, MM Ayala, Z Zhang, M Labrecque, I Aronchik, ... Molecular Cancer Therapeutics 23 (6_Supplement), B022-B022, 2024 | | 2024 |
Ilsa ColemanResearch Scientist, Fred Hutchinson Cancer Research CenterVerified email at fhcrc.org
